Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TIM-3 chimeric antigen receptor + CD33 CCR cytokine-induced killer cells
- Development stage
- Preclinical
- Lead developer
- University of Milano-Bicocca
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
A dual-targeting cell therapy for Acute Myeloid Leukemia (AML) utilizing cytokine-induced killer (CIK) cells. The therapy is engineered using the "IF-BETTER" strategy, which pairs a second-generation chimeric antigen receptor (CAR) with a cytokine-costimulatory receptor (CCR) to simultaneously target CD33 and the leukemic stem cell (LSC) marker TIM-3. A distinguishing feature is the use of a TIM-3-specific single-chain fragment variable (scFv) that preferentially binds to AML-specific hyper-fucosylated and hyper-sialylated N-glycans, thereby enhancing selectivity for leukemic cells and reducing on-target/off-tumor toxicity against healthy TIM-3-expressing immune cells. Developed by researchers at the University of Milano-Bicocca and IRCCS San Gerardo dei Tintori, this approach aims to overcome disease heterogeneity and achieve durable leukemia clearance.
- Other names
- IF-BETTER dual CAR-CIK cellsTIM-3/CD33 dual CAR-CIK cells
02
Targets
CD33 (Myeloid cell surface antigen CD33)HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)
Beyond the preview
Go deeper on TIM-3 chimeric antigen receptor + CD33 CCR cytokine-induced killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TIM-3 chimeric antigen receptor + CD33 CCR cytokine-induced killer cells.